Failure to achieve a threshold bose of CD34+CD110+ progenitor cells in the graft predicts delayed platelet engraftment after autologous stem cell transplantation for multiple myeloma

Biology of Blood and Marrow Transplantation

Volumn 15, Issue 11, 2009, Pages 1386-1393

  Wallington Beddoe, Craig T ^a,b   Gottlieb, David J ^a,b   Garvin, Fran ^a   Antonenas, Vicki ^a   Sartor, Mary M ^a  

^a WESTMEAD HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Engraftment; Myeloma; Platelets; Stem cell transplantation

Indexed keywords

CD34 ANTIGEN; CELL MARKER; THROMBOPOIETIN RECEPTOR;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; ENGRAFTMENT; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NEUTROPHIL; OUTCOME ASSESSMENT; PERIPHERAL BLOOD STEM CELL; THROMBOCYTE TRANSFUSION;

EID: 70350622423     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.06.018     Document Type: Article

References (17)

1. Kyle R, Rajkumar SV. Multiple myeloma. Blood. 2008;111: 2962-2972.
2. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516-2520.
3. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroup Francophone du Myelome. N Engl J Med. 1996;335:91-97.
4. Kumar SK, Dingli D, Lacy MQ, et al. Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis. Am J Hematol. 2008;83:614-617.
5. Qazilbash MH, Saliba RM, Hosing C, et al. Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma. Bone Marrow Transplant. 2007;39:279-283.
6. Barlogie B, Jagannath S, Desikan KR, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood. 1999;93:55-65.
7. Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003;349:2495-2502.
8. + hemopoietic progenitors and platelet recovery after high dose chemotherapy and peripheral blood stem cell transplantation. Haematologica. 1999;84:517-524.
9. Tricot G, Jagannath S, Vesole D, et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood. 1995;85: 588-596.
10. -) human bone marrow progenitor cells: distinct and key interactions with the ligands for c-kit and flt3, and inhibitory effects of TGF-beta and TNF-alpha. J Immunol. 1997;158:5169-5177.
11. Kaushansky K. Thrombopoietin: the primary regulator of megakaryocyte and platelet production. Thromb Haemost. 1995;74:521-525.
12. + progenitor cells in the graft predicts delayed platelet engraftment after autologous stem cell transplantation. Bone Marrow Transplant. 2007;40:851-857.
13. + cells from cryopreserved haemopoietic progenitor cell products. Bone Marrow Transplant. 2005;36:199-204.
14. + cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother. 1996;5:213-226.
15. + megakaryocyte progenitor yield and identify patients at risk of delayed platelet engraftment post-PBPC transplant. Bone Marrow Transplant. 1999;23:539-548.
16. + cells and rapid hematopoietic recovery after peripheral-blood stem-cell transplantation. J Clin Oncol. 1995;13:1922-1932.
17. + cells best predict platelet recovery after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 1998;21: 1217-1222.